Abstract
Background: Inflammatory breast cancer (IBC) carries an ominous prognosis. Before 1988, women with IBC at our institution were treated with neoadjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with or without vincristine and prednisone (CMF/VP). After 1988, women with IBC were treated with cyclophosphamide, doxorubicin, and 5-fluorouracil (FAC). This study compares these two regimens with regard to response and survival.
Methods: The records of all women presenting between January 1973 and December 1991 with a stage IIIB (T4d, any N, MO) breast cancer with proven dermal lymphatic invasion by tumor cells were reviewed retrospectively.
Results: The study comprised 38 women; 28 received CMF (22 CMF, 6 CMF/VP), and 10 received FAC. The overall response rate to induction chemotherapy in the CMF/VP group was 57% (40% PR, 17% CR), and 100% (60% PR, 40% CR) in the FAC group. The median overall survival for women receiving CMF/VP was 18 months compared with 30 months for women receiving FAC (p=0.02). The median disease-free survivals for the CMF/VP and FAC groups were 6 and 24 months, respectively (p<0.001). When comparing responders and nonresponders with CMF/VP induction therapy, the responders had a significantly longer overall median survival (24 versus 10 months) (p<0.001) and disease-free median survival (8 versus 2 months) (p<0.001). All of the five patients remaining alive received FAC with 80% (four of five) having a complete response. These four patients subsequently underwent mastectomy and radiation.
Conclusion: This study suggests that a doxorubicin-containing chemotherapy regimen improves overall and disease-free median survivals when compared with the previously used CMF combination in the treatment of IBC. A favorable response to induction chemotherapy also appeared to be associated with an improved survival.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Levine PH, Steinhorn SC, Ries LG, Aaron JL. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) Program.J Natl Cancer Inst 1985;74:291–7.
Bell C.A System of Operative Surgery, vol 2. Hartford, Connecticut: Hale and Hosmer, 1814:136.
Klotz H.Ueber mastitis carcinomatosa gravidarum et Lactantium. Halle, Germany: Lipke, 1869:30.
Leitch A. Peau d'orange in acute mammyary carcinoma. Its causes and diagnostic value.Lancet 1909;1:861–3.
Learmonth G. Acute mammary carcinoma (Volkman's mastitis carcinomatosis).Can Med Assoc J 1916;6:499–511.
Schumann E. Carcinoma mastitoides.Ann Surg 1911;54:69–77.
Lee BJ, Tannenbaum NE. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of the Memorial Hospital.Surg Gynecol Obstet 1924;39:580–95.
Taylor G, Meltzer A. Inflammatory carcinoma of the breast 1938;33:33–49.
Bozzetti J, Saccozzi R, DeLena M, Salvadori B. Inflammatory cancer of the breast: analysis of 114 cases.J Surg Oncol 1981;18:355–61.
Chris S. Inflammatory carcinoma of the breast: a report of 20 cases and a review of the literature.Br J Surg 1950;38:163–74.
Meyer A, Dockerty M, Harrington S. Inflammatory carcinoma of the breast.Surg Gynecol Obstet 1948;87:417–24.
Stocks L, Patterson F. Inflammatory carcinoma of the breast.Surg Gynecol Obstet 1976;143:885–9.
Barker J, Montague E, Peters L, et al. Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy.Cancer 1980;45:625–9.
Dao T, McCarthy J. Treatment of inflammatory carcinoma of the breast.Surg Gynecol Obstet 1957;105:289–94.
Richards G, Lewiston E. Inflammatory carcinoma of the breast.Surg Gynecol Obstet 1961;113:729–32.
Wang C, Griscom N. Inflammatory carcinoma of the breast: Results following orthovoltage and supervoltage radiation therapy.Clin Radiol 1964;15:168–74.
Rogers C, Fitts W. Inflammatory carcinoma of the breast. A critique of therapy.Surgery 1956;39:367–70.
Barber K, Dockerty M, Clagett O. Inflammatory carcinoma of the breast.Surg Gynecol Obstet 1961;112:406–10.
Donegan W. Staging and end results. In: Spratt J Jr, Donegan W, eds.Cancer of the breast. Philadelphia: WB Saunders, 1967:117–61.
Nussbaum H, Kagan A, Gilbert H, et al. Management of inflammatory breast carcinoma.Breast 1977;3:25–9.
Kaplan E, Meier P. Nonparametric estimation from incomplete observations.J Am Stat Assoc 1958;53:457–86.
Cox D. Regression models and life-tables.J R Stat Soc B 1972;34:187–220.
Jaiyesimi I, Buzdar A, Hortobagyi G. Inflammatory breast cancer: a review.J Clin Oncol 1992;10:1014–24.
Haagensen C.Diseases of the breast, 2nd ed. Philadelphia: WB Saunders, 1971:576–84.
Rouesse J, Friedman S, Sarrazin D, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussey.J Clin Oncol 1986;4:1765–71.
Chevallier B, Asselain B, Kunlin A, Veyret C, et al. Inflammatory breast cancer: determination of prognostic factors by univariate and multivariate analysis.Cancer 1987;60:897–902.
Kohail H, Elias E, El-Noweim S, Bashirelahi N, et al. A multifactorial analysis of steroid hormone receptor in stage I and II breast cancer.Ann Surg 1985;201:61–7.
Veronesi A, Frustaci S, Tirelli U, et al. Tamoxifen therapy in postmenopausal advanced breast cancer: efficacy at the primary tumor site in 46 evaluable patients.Tumori 1981;67:235–8.
Sherry M, Johnson D, Page D, Greco F, et al. Inflammatory carcinoma of the breast: clinical review and summary of the Vanderbilt experience with multi-modality therapy.Am J Med 1985;79:355–64.
Muss H, White D, Richards F, et al. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer.Cancer 1978;42:2141–8.
Bull J, Tormey D, Li S, et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.Cancer 1978;41:1649–57.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bauer, R.L., Busch, E., Levine, E. et al. Therapy for inflammatory breast cancer: Impact of doxorubicin-based therapy. Annals of Surgical Oncology 2, 288–294 (1995). https://doi.org/10.1007/BF02307059
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02307059